{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:01:12Z","timestamp":1790596872450,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Breast cancer (BC) patients with pathogenic germline\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      mutations (\n                      <jats:italic>gBRCA1\/2mut)<\/jats:italic>\n                      have a substantially increased risk of ovarian cancer (OC). Risk-reducing bilateral salpingo-oophorectomy (RRSO) remains the only effective preventive strategy. However, data on the utilization and time to RRSO in g\n                      <jats:italic>BRCA<\/jats:italic>\n                      mut BC patients are limited.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study included 148 patients with\n                      <jats:italic>gBRCA1\/2mut<\/jats:italic>\n                      BC treated at the Hereditary Breast and Ovarian Cancer Center, University Hospital Erlangen, between 2012 and 2024. Clinical, pathological, treatment-related, and genetic data were collected and analyzed from electronic records. Time to RRSO at date of BC surgery was calculated for all patients, and stratified according guideline recommendations for RRSO, using the Kaplan\u2013Meier method.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In this cohort of 148 patients with\n                      <jats:italic>gBRCAmut<\/jats:italic>\n                      BC, 60.8% harbored a\n                      <jats:italic>gBRCA1<\/jats:italic>\n                      and 39.2% a\n                      <jats:italic>gBRCA2<\/jats:italic>\n                      mutation. BC was diagnosed at the mean age of 47.1\u00a0years, 73.6% presenting at UICC stage I\u2013II. 47.9% of patients presented with triple-negative BC, 38.4% of patients with hormone receptor (HR)-positive\/human epidermal growth factor receptor 2 (HER2)-negative BC and 8.9% with HER2-positive BC. 101 patients (68.2%) additionally underwent RRSOs. The 12-month RRSO-free probability was 0.58 (95% CI 0.50\u20130.68) and the 24-month RRSO-free probability 0.39 (95% CI 0.31\u20130.49). Occult OC was detected in three patients at the time of RRSO during BC follow-up, four patients without RRSO were diagnosed with OC after BC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      In real-world setting, RRSO is a common prevention in g\n                      <jats:italic>BRCA<\/jats:italic>\n                      mut BC follow-up. The majority of patients undergo surgery within the first two years following a BC diagnosis. Survival outcomes among patients with BC have improved substantially in recent years. Consequently, developing OC in g\n                      <jats:italic>BRCA<\/jats:italic>\n                      mut BC individuals still remains a risk. RRSO should therefore continue to be offered and discussed in accordance with current guidelines, even in the context of a BC diagnosis.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00404-026-08581-2","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:08:56Z","timestamp":1790593736000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk-reducing salpingo-oophorectomy in patients with gBRCA-mutated breast cancer"],"prefix":"10.1007","volume":"313","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5280-2800","authenticated-orcid":false,"given":"Niklas","family":"Amann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Kr\u00fcckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Br\u00fcckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Gocke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Runz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Heindl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Carolin","family":"Hack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Emons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Peter","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Matthias","family":"Beckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"H\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"09","key":"8581_CR1","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1055\/a-1222-0042","volume":"80","author":"B Ataseven","year":"2020","unstructured":"Ataseven B et al (2020) Prevalence of BRCA1 and BRCA2 mutations in patients with primary ovarian cancer \u2013 does the German checklist for detecting the risk of hereditary breast and ovarian cancer adequately depict the need for consultation? Geburtshilfe Frauenheilkd 80(09):932\u2013940","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"4","key":"8581_CR2","first-page":"161","volume":"94","author":"MW Beckmann","year":"1997","unstructured":"Beckmann MW et al (1997) Hochrisikofamilien mit Mamma- und Ovarialkarzinomen: M\u00f6glichkeiten der Beratung, genetischen Analyse und Fr\u00fcherkennung. Dtsch Arztebl International 94(4):161","journal-title":"Dtsch Arztebl International"},{"issue":"5","key":"8581_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1913948","volume":"384","author":"L Dorling","year":"2021","unstructured":"Dorling L et al (2021) Breast cancer risk genes - association analysis in more than 113,000 women. N Engl J Med 384(5):428\u2013439","journal-title":"N Engl J Med"},{"issue":"23","key":"8581_CR4","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402\u20132416","journal-title":"JAMA"},{"issue":"1","key":"8581_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ygyno.2018.05.011","volume":"150","author":"J Kotsopoulos","year":"2018","unstructured":"Kotsopoulos J et al (2018) Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol 150(1):85\u201391","journal-title":"Gynecol Oncol"},{"issue":"2","key":"8581_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.6004\/jnccn.2026.0007","volume":"24","author":"HH Cheng","year":"2026","unstructured":"Cheng HH et al (2026) NCCN Guidelines\u00ae insights: genetic\/familial high-risk assessment: breast, ovarian, pancreatic, and prostate, version 2.2026. J Natl Compr Canc Netw 24(2):2\u201310","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"8581_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00432-025-06388-3","volume":"152","author":"N Amann","year":"2025","unstructured":"Amann N et al (2025) Quality of care before and after initial certification at a German certified hereditary breast and ovarian cancer center. J Cancer Res Clin Oncol 152(1):13","journal-title":"J Cancer Res Clin Oncol"},{"issue":"50","key":"8581_CR8","first-page":"6514","volume":"102","author":"K Schmutzler","year":"2005","unstructured":"Schmutzler K et al (2005) Famili\u00e4rer Brust- und Eierstockkrebs: Von der Forschung zur Regelversorgung. Dtsch Arztebl International 102(50):6514","journal-title":"Dtsch Arztebl International"},{"issue":"39","key":"8581_CR9","first-page":"647","volume":"120","author":"J Schmitt","year":"2023","unstructured":"Schmitt J et al (2023) Initial cancer treatment in certified versus non-certified hospitals. Dtsch Arztebl Int 120(39):647\u2013654","journal-title":"Dtsch Arztebl Int"},{"issue":"44","key":"8581_CR10","first-page":"6996","volume":"104","author":"MW Beckmann","year":"2007","unstructured":"Beckmann MW et al (2007) Onkologie Dreistufenmodell optimiert Behandlung unter Kostendeckung Wie die k\u00fcnftigen Strukturen der onkologischen Versorgung in Deutschland aussehen sollten. Dtsch Arztebl Int 104(44):6996","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"8581_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00404-013-3084-5","volume":"289","author":"S Wesselmann","year":"2014","unstructured":"Wesselmann S, Beckmann MW, Winter A (2014) The concept of the certification system of the German Cancer Society and its impact on gynecological cancer care. Arch Gynecol Obstet 289(1):7\u201312","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"8581_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/GME.0000000000001883","volume":"29","author":"G Grandi","year":"2021","unstructured":"Grandi G et al (2021) The challenging screen detection of ovarian cancer in BRCA mutation carriers adhering to a 6-month follow-up program: results from a 6-years surveillance. Menopause 29(1):63\u201372","journal-title":"Menopause"},{"issue":"1","key":"8581_CR13","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ygyno.2021.07.034","volume":"163","author":"A Na\u00f1ez","year":"2021","unstructured":"Na\u00f1ez A et al (2021) Ovarian cancer surveillance in the clinical follow up of women with known BRCA1 or BRCA2 pathogenic variants in a large health care system. Gynecol Oncol 163(1):134\u2013141","journal-title":"Gynecol Oncol"},{"issue":"1","key":"8581_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","volume":"34","author":"C Sessa","year":"2023","unstructured":"Sessa C et al (2023) Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline\u2606. Ann Oncol 34(1):33\u201347","journal-title":"Ann Oncol"},{"issue":"5","key":"8581_CR15","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMra1503523","volume":"374","author":"LC Hartmann","year":"2016","unstructured":"Hartmann LC, Lindor NM (2016) The role of risk-reducing surgery in hereditary breast and ovarian cancer. N Engl J Med 374(5):454\u2013468","journal-title":"N Engl J Med"},{"issue":"21","key":"8581_CR16","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa020119","volume":"346","author":"ND Kauff","year":"2002","unstructured":"Kauff ND et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346(21):1609\u20131615","journal-title":"N Engl J Med"},{"issue":"2","key":"8581_CR17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/jnci\/djn442","volume":"101","author":"TR Rebbeck","year":"2009","unstructured":"Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101(2):80\u201387","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"8581_CR18","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/jama.2010.1237","volume":"304","author":"SM Domchek","year":"2010","unstructured":"Domchek SM et al (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304(9):967\u2013975","journal-title":"JAMA"},{"issue":"6","key":"8581_CR19","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S1470-2045(25)00152-4","volume":"26","author":"E Blondeaux","year":"2025","unstructured":"Blondeaux E et al (2025) Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study. Lancet Oncol 26(6):759\u2013770","journal-title":"Lancet Oncol"},{"key":"8581_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ygyno.2025.07.030","volume":"201","author":"AI Apostol","year":"2025","unstructured":"Apostol AI et al (2025) Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant. Gynecol Oncol 201:44\u201352","journal-title":"Gynecol Oncol"},{"issue":"1","key":"8581_CR21","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ygyno.2004.09.039","volume":"96","author":"KA Metcalfe","year":"2005","unstructured":"Metcalfe KA et al (2005) The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol 96(1):222\u2013226","journal-title":"Gynecol Oncol"},{"issue":"3","key":"8581_CR22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/GME.0000000000001737","volume":"28","author":"G Grandi","year":"2021","unstructured":"Grandi G et al (2021) Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants\u2019 characteristics at surgery: a prospective study. Menopause 28(3):263\u2013270","journal-title":"Menopause"},{"issue":"1","key":"8581_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41416-019-0446-1","volume":"121","author":"K Metcalfe","year":"2019","unstructured":"Metcalfe K et al (2019) International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br J Cancer 121(1):15\u201321","journal-title":"Br J Cancer"},{"issue":"3","key":"8581_CR24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10549-025-07821-4","volume":"214","author":"CB Willert","year":"2025","unstructured":"Willert CB et al (2025) Time trends, uptake, and oncological effects of risk-reducing surgeries in 3067 Danish BRCA1\/2 carriers: a population-based study with matched controls. Breast Cancer Res Treat 214(3):355\u2013366","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"8581_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00404-025-08270-6","volume":"313","author":"A Kr\u00fcckel","year":"2026","unstructured":"Kr\u00fcckel A et al (2026) Genetic tumor syndromes in female cancer: insights into inherited cancer predisposition and clinical implications. Arch Gynecol Obstet 313(1):38","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"8581_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2307\/2530286","volume":"38","author":"R Brookmeyer","year":"1982","unstructured":"Brookmeyer R, Crowley J (1982) A confidence interval for the median survival time. Biometrics 38(1):29\u201341","journal-title":"Biometrics"},{"issue":"13","key":"8581_CR27","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1200\/JCO.2016.69.9330","volume":"35","author":"AN Rosenthal","year":"2017","unstructured":"Rosenthal AN et al (2017) Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom familial ovarian cancer screening study. J Clin Oncol 35(13):1411\u20131420","journal-title":"J Clin Oncol"},{"issue":"14","key":"8581_CR28","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1158\/1078-0432.CCR-15-2750","volume":"23","author":"SJ Skates","year":"2017","unstructured":"Skates SJ et al (2017) Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk \u2013 combined results from two screening trials. Clin Cancer Res 23(14):3628\u20133637","journal-title":"Clin Cancer Res"},{"issue":"15","key":"8581_CR29","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","volume":"32","author":"AP Finch","year":"2014","unstructured":"Finch AP et al (2014) Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 32(15):1547\u20131553","journal-title":"J Clin Oncol"},{"issue":"11","key":"8581_CR30","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1158\/1940-6207.CAPR-21-0141","volume":"14","author":"C Conduit","year":"2021","unstructured":"Conduit C et al (2021) Bilateral salpingo-oophorectomy and breast cancer risk for BRCA1 and BRCA2 mutation carriers: assessing the evidence. Cancer Prev Res 14(11):983\u2013994","journal-title":"Cancer Prev Res"},{"issue":"11","key":"8581_CR31","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djt095","volume":"105","author":"N Mavaddat","year":"2013","unstructured":"Mavaddat N et al (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105(11):812\u2013822","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"8581_CR32","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10549-019-05162-7","volume":"175","author":"J Kotsopoulos","year":"2019","unstructured":"Kotsopoulos J et al (2019) Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 175(2):443\u2013449","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"8581_CR33","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10689-015-9825-9","volume":"14","author":"NN Basu","year":"2015","unstructured":"Basu NN et al (2015) Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis. Fam Cancer 14(4):531\u2013538","journal-title":"Fam Cancer"},{"issue":"6","key":"8581_CR34","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S1470-2045(25)00156-1","volume":"26","author":"H Hassan","year":"2025","unstructured":"Hassan H et al (2025) Long-term health outcomes of bilateral salpingo-oophorectomy in BRCA1 and BRCA2 pathogenic variant carriers with personal history of breast cancer: a retrospective cohort study using linked electronic health records. Lancet Oncol 26(6):771\u2013780","journal-title":"Lancet Oncol"},{"issue":"6","key":"8581_CR35","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1136\/ijgc-2023-004377","volume":"33","author":"MP Steenbeek","year":"2023","unstructured":"Steenbeek MP et al (2023) TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol. Int J Gynecol Cancer 33(6):982\u2013987","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"8581_CR36","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ygyno.2016.08.336","volume":"143","author":"M Zakhour","year":"2016","unstructured":"Zakhour M et al (2016) Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers. Gynecol Oncol 143(2):231\u2013235","journal-title":"Gynecol Oncol"},{"issue":"2","key":"8581_CR37","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ygyno.2020.02.006","volume":"157","author":"SK Rush","year":"2020","unstructured":"Rush SK et al (2020) Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: a large prospective single institution experience. Gynecol Oncol 157(2):514\u2013520","journal-title":"Gynecol Oncol"},{"issue":"29","key":"8581_CR38","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1200\/JCO.2013.54.1987","volume":"32","author":"ME Sherman","year":"2014","unstructured":"Sherman ME et al (2014) Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol 32(29):3275\u20133283","journal-title":"J Clin Oncol"},{"issue":"14","key":"8581_CR39","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1200\/JCO.22.01237","volume":"41","author":"IAS Stroot","year":"2023","unstructured":"Stroot IAS et al (2023) High-grade serous carcinoma at risk-reducing salpingo-oophorectomy in asymptomatic carriers of BRCA1\/2 pathogenic variants: prevalence and clinical factors. J Clin Oncol 41(14):2523\u20132535","journal-title":"J Clin Oncol"},{"issue":"3","key":"8581_CR40","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/AOG.0000000000003702","volume":"135","author":"S Piedimonte","year":"2020","unstructured":"Piedimonte S et al (2020) Occult tubal carcinoma after risk-reducing salpingo-oophorectomy: a systematic review. Obstet Gynecol 135(3):498\u2013508","journal-title":"Obstet Gynecol"},{"issue":"10","key":"8581_CR41","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1200\/JCO-25-01648","volume":"44","author":"AI Apostol","year":"2026","unstructured":"Apostol AI et al (2026) Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic\/Likely Pathogenic Variant in BRCA1 or BRCA2. J Clin Oncol 44(10):883\u2013892","journal-title":"J Clin Oncol"},{"issue":"05","key":"8581_CR42","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1055\/a-1933-9469","volume":"17","author":"N Amann","year":"2023","unstructured":"Amann N et al (2023) Heredit\u00e4re Karzinome in der Gyn\u00e4kologie. Frauenheilkd Up2date 17(05):477\u2013493","journal-title":"Frauenheilkd Up2date"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-026-08581-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-026-08581-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-026-08581-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:32:45Z","timestamp":1790595165000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-026-08581-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8581"],"URL":"https:\/\/doi.org\/10.1007\/s00404-026-08581-2","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"23 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.A. received honoraria for lectures and participation in advisory boards: Aurikamed, Gilead, Georg Thieme Verlag, Novartis and Pfizer. N.A. also received support for attending meetings from AstraZeneca, Novartis, and Pfizer. K.W. has no conflict of interests. P.Z. has no conflict of interests. A.K. received lecture fees from Gilead and Novartis, honoraria for written scientific work from Georg Thieme Verlag as well as support for attending meetings from Lilly. L.B. received honoraria for lectures: Gilead. L.B. received support for attending meetings from AstraZeneca; J.G. has no conflicts of interest. S.N. has no conflicts of interest. C.M. received honoraria for research from Novartis. F.H. Heindl has received honoraria from AstraZeneca, Novartis, and Lilly. C.C.H. J.G. has no conflicts of interest. P.A.F received personal fees from Novartis, Pfizer, Daiichi-Sankyo, AstraZeneca, Eisai, Merck Sharp & Dohme, Lilly, SeaGen, Roche, Agendia, Gilead, Mylan, Menarini, Veracyte, GuardantHealth, and grants from Biontech, Pfizer, Cepheid, during the conduct of the study; and Translational Research in Oncology. M.W.B. has no conflicts of interest. M.H. received institutional research support from Helsinn Healthcare SA, institutional research support from Gilead, honoraria from Lilly Deutschland GmbH, Thieme, and travel support from Novartis, Lilly Deutschland GmbH, and AstraZeneca.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Faculty of Medicine at Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU) (ref. number 24\u2013440-Br). All procedures were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Supplemental agreement to the study was waived due to the retrospective study design, including only anonymized data analysis. There was no use of animal research within this project.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"278"}}